A failed Soviet-era spacecraft that aimed for Venus is expected to crash back to Earth tonight
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
A Soviet-era spacecraft that was designed to make a soft landing on Venus — but instead remained trapped in Earth orbit for decades — is slated to fall from the sky Friday night or early Saturday, according to the latest estimates from experts.
The object, referred to as Cosmos 482 or Kosmos 482, is believed to be a capsule launched by the Soviet Union in March 1972 that failed en route to a transfer orbit that would have taken it to Venus to study its environment.
In the decades since, the object has circled Earth aimlessly as it was slowly dragged back toward home.
Astronomers and space traffic experts have had their eyes on the object for years now as its orbital path has slowly reached lower and lower altitudes, a result of the subtle atmospheric drag that exists even hundreds of miles away from Earth.
The cylinder-shaped craft, which is about 3 feet (1 meter) in diameter, is now predicted to crash back to Earth overnight. Cosmos 482 is on track to hit the ground or ocean roughly between 10 p.m. and 6:30 a.m. ET, according to four analyses of the object from various institutions, including the European Space Agency and the federally funded US research group Aerospace Corporation.
That guidance is still in line with predictions issued by space traffic experts earlier this week. The estimated time frame of the vehicle's final descent will narrow as the event approaches.
Because of the sheer complexity of spaceflight and unpredictable factors, such as space weather, it can be extremely difficult to pinpoint exactly when or where an object will fall out of orbit.
This particular piece of space junk likely won't pose a risk to people on the ground.
'This object was designed to survive reentering Venus, so there's fair odds that it'll survive coming back (to Earth) in one piece,' said Marlon Sorge, a space debris expert with The Aerospace Corporation, on Monday. 'That actually makes the risk less … because it would stay intact.'
Often, when spaceborne garbage hurtles back toward Earth, objects such as defunct rocket parts are torn apart by the jarring physics as they can slam into Earth's thick inner atmosphere while still traveling at more than 17,000 miles per hour (27,000 kilometers per hour).
Each of the pieces from the rocket part can then pose a threat to the area where it lands.
But Cosmos 482 is uniquely suited to make the trip home in one piece. The spacecraft has a substantial heat shield that protects the vehicle from the intense temperatures and pressures that can build up during reentry.
And because Cosmos 482 was designed to reach the surface of Venus — where the atmosphere is 90 times denser than Earth's — the probe is likely to reach the ground intact.
The Soviet Union's Space Research Institute, or IKI, ran a groundbreaking Venus exploration program amid the 20th century space race.
Venera, as the program was called, sent a series of probes toward Venus in the 1970s and '80s, with several spacecraft surviving the trip and beaming data back to Earth before ceasing operations.
Of the two Venera vehicles that were launched in 1972 , however, only one made it to Venus.
The other, a spacecraft sometimes cataloged as V-71 No. 671, did not. And that's why researchers believe the object that space traffic experts are tracking is Cosmos 482. (Beginning in the 1960s, Soviet vehicles left in Earth orbit were each given the Cosmos name and a numerical designation for tracking purposes, according to NASA.)
While a landing on dry ground is unlikely, it's not impossible. The Cosmos 482 object's trajectory shows it could hit anywhere within a broad swath of land that includes 'the whole of Africa, South America, Australia, the USA, parts of Canada, parts of Europe, and parts of Asia,' said Marco Langbroek, a lecturer and space traffic expert at Delft Technical University in the Netherlands, via email.
Sorge emphasized that if Cosmos 482 hits the ground after its final descent tonight, onlookers are advised to keep their distance. The aged spacecraft could leak dangerous fuels or pose other risks to people and property.
'Contact the authorities,' Sorge urged. 'Please don't mess with it.'
Legally speaking, the object also belongs to Russia. According to rules mapped out in the 1967 Outer Space Treaty — which remains the primary document underpinning international law on the matter — the nation that launched an object to space retains ownership and responsibility for it even if it crashes back to Earth decades after launch.
Though defunct objects in space routinely fall out of orbit, most pieces of debris disintegrate entirely during the reentry process.
But the world is in the midst of a new space race, with commercial companies such as SpaceX launching hundreds of new satellites to orbit each year. That burst in activity has raised alarms across the space traffic community, as experts are seeking to ensure that objects don't collide in space or pose a risk to humans if they make an uncontrolled descent back home.
Safety standards have drastically improved since the 20th century space race when the Soviet Venus probe was launched, noted Parker Wishik, a spokesperson for The Aerospace Corporation.
Still, incidents such as the impending impact event are a stark reminder.
'What goes up must come down,' Wishik said. 'What you put up in space today might affect us for decades to come.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
India to send first astronaut on mission to International Space Station
The first Indian astronaut to visit the International Space Station is due to blast off as part of an effort by the world's most populous nation to catch up with the US, Russia and China in human space flight missions. Shubhanshu Shukla, a 39-year-old air force fighter pilot, is is part of four-person mission launching on Tuesday from the US with the private company Axiom Space, which is using a SpaceX capsule. He will be the third astronaut of Indian origin to reach orbit, following Rakesh Sharma, who was part of a 1984 flight onboard a Soviet Soyuz spacecraft, and Kalpana Chawla, who was born in India but became a US citizen and flew on two space shuttle missions, including the 2003 Columbia flight that ended in disaster when the spacecraft disintegrated, killing all seven astronauts onboard. 'I truly believe that even though, as an individual, I am travelling to space, this is the journey of 1.4 billion people,' Shukla was quoted as saying by the Hindu newspaper this year. Shukla said he hoped to 'ignite the curiosity of an entire generation in my country'. India's department of space has called the trip a 'defining chapter' in its ambitious space exploration programme. The International Space Station mission (ISS) 'stands as a symbol of a confident, forward-looking nation ready to reclaim its place in the global space race', the agency said before the launch. 'His journey is more than just a flight – it's a signal that India is stepping boldly into a new era of space exploration.' New Delhi has paid more than $60m for the mission, according to Indian media reports. The prime minister, Narendra Modi, has announced plans to send a person to the moon by 2040. The Indian Space Research Organisation, meanwhile, is planning to launch its own human spaceflight mission, called Gaganyaan, or 'sky craft' in Hindi, in 2027. Shukla is a contender to be part of that trip. Shukla trained at the Yuri Gagarin Cosmonaut Training Center in Russia in 2020, before undertaking further training at the ISRO's centre in Bengaluru. He has said the journey aboard the Axiom Mission 4, and the expected 14 days on the ISS, will provide 'invaluable' lessons to bring back home. Shukla will be led by the mission commander, Peggy Whitson, a former Nasa astronaut and an Axiom employee, and joined by the European Space Agency astronaut Sławosz Uznański-Wiśniewski, of Poland, and Tibor Kapu, of Hungary. Related: How space exploration can improve life on Earth | Leigh Phillips They will conduct 60 scientific studies, including microgravity research, earth observation, and life, biological and material sciences experiments. India's space programme has grown considerably in size and momentum in the last decade, matching the achievements of established powers at a much cheaper price. In August 2023, it became the fourth nation to land an unmanned craft on the moon after Russia, the US and China. Agence France-Presse contributed to this report
Yahoo
16 hours ago
- Yahoo
What if your house changed color with the seasons? This ‘climate-responsive' paint could make it happen
Editor's Note: Design for Impact is a series spotlighting innovative solutions for communities affected by the climate crisis, natural disasters and other humanitarian emergencies. When Joe Doucet bought a new house in Katonah, New York, he wanted to make it as environmentally friendly as possible. As a designer and inventor, he immediately found himself wondering whether the exterior of his home could play a role in mitigating the effects of climate change. 'One of the things I had not really considered before was: What color should I paint the house?' he told CNN, speaking in a video call. It's well known that light-colored buildings reflect heat and stay cooler while darker ones absorb — just compare chilly Scandinavia's black housing tradition to the whitewashed homes found across warm Mediterranean countries. But what shade would perform best in a climate like New York's, with hot summers but dark and snowy winters? Doucet started by 3D-printing small scale models of his house, complete with similar levels of insulation, and painting them in different colors. Over the course of a year, he found that in winter the inside temperature of the black model was on average 7 degrees Fahrenheit warmer than the white one. In summer, the white model house was 12 degrees Fahrenheit cooler. 'The answer wasn't, 'Should I paint it black or white?' The answer was: It should be black in winter and white in summer,' he said of the findings. 'It is not really feasible to paint a house twice a year. I began to think, 'Surely there are other ways of doing this?'' Doucet's solution was inspired by his childhood interest in mood rings, which feature manmade 'stones' that change appearance according to the wearer's finger temperature. 'I recall a fascination I had with a mood ring I received as a child and really trying to dig in and understand what it was,' he explained. 'I knew, even as 7-year-old, that (the ring's changing color) had nothing to do with my mood, that there was some type of chemistry at play. The chemistry that creates that change is very, very similar to what I used.' The process in question is called a thermochromic response, which refers to how chains of liquid crystals react to atmospheric temperature. In a mood ring, these liquid crystals are contained within the 'gemstone,' causing its color to change. Doucet developed a kind of thermochromic pigment containing the crystals and started experimenting with a tin of ordinary housepaint and different additives. The result was a substance that could change color by absorbing ultra-violet light (which produces heat) above a certain temperature. Despite what he called the 'great success' of his initial trials, Doucet found his new paints would slowly degrade in the sunlight. But after experimenting for another year, the designer solved the issue with the help of a protective additive. His climate-responsive paint, as he dubs it, appears 'very, very dark gray' below 77 degrees Fahrenheit and gradually turns lighter as the temperature rises. Doucet has since filed a patent application for the technology. He admits his invention won't be especially useful for people in consistently hot or cold climates. But Doucet believes his paint could be a 'game changer' for those living in the world's temperate zones — including large parts of North America, Europe and Asia — where average temperatures are typically higher than 50 degrees Fahrenheit in the warmest months but no lower than 26.6 degrees Fahrenheit in the coldest. Last year was the hottest year on record. It was also the first calendar year to breach 1.5 degrees Celsius above pre-industrial levels, a critical climate threshold. Doucet sees his invention as a direct response to this changing climate, rather than innovative new technology: 'This could have been done 70 years ago, there was just no need for it,' he explained. 'Climate change wasn't an issue at the time.' But more than helping homeowners respond to rising temperatures, Doucet's invention could have an impact on their climate pollution amid increasing energy costs and dependence on air conditioning (in 2020, 88% of US households used AC, up from 77% two decades ago). The operation of buildings accounts for 30% of global energy consumption, according to the International Energy Agency. But homes with improved thermal control consume less power by reducing demand for both air conditioning and heating. Doucet's modeling 'conservatively' predicts his paint could help households save between 15% to 30% on their energy costs. Beyond the science, Doucet believes there is beauty in the idea that buildings might shift with the seasons, like the leaves on a tree. 'There's something poetic about seeing the built environment and the built world change with the seasons in the way nature does,' he said. He also notes that new climate-responsive paints need not only change from white to black: 'You can tint this pretty much any color,' he explained. A house could turn light blue in warmer months before turning a darker blue in the wintertime, he offered as an example. So, with his prototype technology developed, how long until people can paint their houses with it? 'Five to 10 years,' said Doucet, caveating that its proliferation will depend on how people react to it. So far, he said, responses have ranged from 'amazing' to 'I don't believe you.' The changing political climate may also impact his product's route to market. President Donald Trump's promise to 'terminate' his predecessor Joe Biden's clean energy policies — which he has called the 'Green New Scam' — has created an uncertain climate for eco-investing. Doucet, who is also involved with an wind energy venture, says the resulting change in how investors respond to green projects has made him reluctant to raise venture capital and go at it alone. Instead, he hopes to find a partner that can bring the invention to market, like a paint company, a chemical company or some combination of both. 'When situations change,' he said, referencing the Trump administration's plans to cut subsidies and tax rebates for clean energy projects, 'you need to change with them.' Nevertheless, Doucet appears confident that his creation has a potentially huge market. Not only could the paint be used on homes, but also larger buildings like schools, factories and other structures requiring a controlled internal environment. Though he is careful not to oversell the impact of his invention. 'There is no single solution to climate change. It's a series of steps and small actions,' he said. 'But this could be a meaningful one.'
Yahoo
16 hours ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data